AXGNAxogen, Inc.

HealthcareUSD
$51.57

Price

$51.57+267%1Y
1M+30%1Y+267%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Top tier
9/10
Value48
Quality66
Momentum88
Growth74
Strongest Momentum, weakest Value · ranked vs Healthcare peers. The five questions below judge the company on its own terms.
What they do

We are the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. We are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries. We provide innovative, clinically proven, and economically effective repair solutions for surgeons and healthcare providers.

In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR

P/E (TTM)-
Market Cap$2.38B
1Y Return+267%
5Y Return+153%

Axogen, Inc. (AXGN) reported revenue of $61M in Q1 2026 (quarter ended March 31, 2026), up 27% from the same quarter a year earlier. That came with a gross margin of 75% and net loss of $20M. For the full year FY2025, revenue was $225M (+20% year on year) and net income −$16M.

Raw charts

10 series · TTM

As reported to the SEC, without any scoring.

Medical Devices

Ranks #8 of 35 by Smart Score

Compare peers
ESTA+2.1%
Establishment Labs Holdings Inc.
BFLY+3.2%
Butterfly Network, Inc.
TMDX+0.17%
TransMedics Group, Inc.
NEOG+3.6%
Neogen Corporation
UFPT+4.0%
UFP Technologies, Inc.
ALMR+13%
Alamar Biosciences, Inc.